Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice

International Immunology

Volumn 21, Issue 10, 2009, Pages 1175-1183

  Gil González, Lázaro ^a   López, Carlos ^a   Lazo, Laura ^a   Valdés, Iris ^a   Marcos, Ernesto ^a   Alonso, Ruby ^b   Gambe, Ailyn ^a   Martín, Jorge ^a   Romero, Yaremis ^a   Guzmán, María G ^c   Guillén, Gerardo ^a   Hermida, Lisset ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Capsid protein; Cell mediated immunity; Dengue virus; Virus like particles

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CAPSID PROTEIN; DENGUE VACCINE; EPITOPE; GAMMA INTERFERON; PLACEBO; RECOMBINANT NUCLEOCAPSID LIKE PARTICLE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROTECTION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DENGUE VIRUS; DRUG SCREENING; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE; VIRUS ENCEPHALITIS; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; ENCEPHALITIS, VIRAL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; NUCLEOCAPSID; RECOMBINANT PROTEINS;

EID: 70349514677     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxp082     Document Type: Article

References (50)

1. Gubler, D. J. and Kuno, G. 1997. Viral pathogenesis of dengue infections. In Gubler, D. J. and Kuno, G., eds., Dengue and Dengue Hemorrhagic Fever, p. 273. CAB International, Wallingford.
2. Beaumier, C. M., Mathew, A., Bashyam, H. S. and Rothman, A. L. 2008. Cross-reactive memory CD8+ T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. J. Infect. Dis. 197:608.
3. Lobigs, M., Mullbacher, A. and Lee, E. 2004. Evidence that a mechanism for efficient flavivirus budding upregulates MHC class I. Immunol. Cell Biol. 82:184.
4. Mongkolsapaya, J., Dejnirattisai, W., Xu, X. N. et al. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:921.
5. Mongkolsapaya, J., Duangchinda, T., Dejnirattisai, W. et al. 2006. T cell response in dengue hemorrhagic fever: Are cross-reactive T cells suboptimal? J. Immunol. 176:3821.
6. Mangada, M. M. and Rothman, A. L. 2005. Altered cytokine response of dengue-specific CD4+ T cells to heterologous serotypes. J. Immunol. 175:2676.
7. Imrie, A., Meeks, J., Gurary, A. et al. 2007. Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J. Virol. 81:10081.
8. Van der Most, R. G., Murali-Krishna, K., Ahmed, R. and Strauss, J. H. 2000. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 4:8094.
9. Gil, L., López, C., Blanco, A. et al. 2009. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol. 22:23.
10. Yauch, L. E., Zellweger, R. M., Kotturi, M. F. et al. 2009. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182:4865.
11. Thomas, S. J., Hombach, J. and Barrett, A. 2009. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 27:355.
12. Vaughn, D. W., Scherer, J. M. and Sun, W. 2008. Resistance to infection. In Halstead, S. B., ed., Dengue - Tropical Medicine: Science and Practice, p. 123. Imperial College Press, London.
13. Sabchareon, A., Lang, J., Chanthavanich, P. et al. 2004. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr. Infect. Dis. J. 23:99.
14. Simasathien, S., Thomas, S. J., Watanaveeradej, V. et al. 2008. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am. J. Trop. Med. Hyg. 78:426.
15. Noad, R. and Roy, P. 2003. Virus-like particles as immunogens. Trends Microbiol. 11:438.
16. Gagnon, S. J., Zeng, W., Kurane, I. and Ennis, F. A. 1996. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocytes clones. J. Virol. 70:141.
17. Lazo, L., Hermida, L., Zulueta, A. et al. 2007. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 25:1064.
18. Clarke, D. H. and Casals, J. 1958. Techniques for hemagglutination and hemagglutination-inhibition with arthropod borne virus. Am. J. Trop. Med. Hyg. 7:561.
19. López, C., Gil, L., Lazo, L. et al. 2009. The in vitro assembly of nucleocapsid-like particles from the purified recombinant capsid protein of dengue 2. Arch. Virol. 154:695.
20. Kaufman, B. M., Summers, P. L., Dubois, D. R. and Eckels, K. H. 1987. Monoclonal against dengue-2 virus E glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36:427.
21. Peters, B. and Sette, A. 2005. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6:132.
22. Morens, D. M., Halstead, S. B. and Repik, P. M. 1985. Simplified plaque reduction assay for Dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test standard plaque reduction neutralization. J. Clin. Microbiol. 22:250.
23. Schlesinger, J. J., Brandis, M. W. and Walsh, E. E. 1987. Protection of mice against dengue-2 encephalitis by immunization with dengue-2 virus non-structural glycoprotein NS1. J. Gen. Virol. 68:853.
24. Sette, A. and Sidney, J. 1998. HLA supertypes and supermotifs: A functional perspective HLA polymorphism. Curr. Opin. Immunol. 10:478.
25. Paliard, X., Liu, Y., Wagner, R., Wolf, H., Baenziger, J. and Walker, C. M. 2000. Priming of strong broad and long-lived HIV type 1 p55gap-specific CD8+ cytotoxic T cells after administration of a virus-like particles vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 16:273.
26. Murata, K., Lechmann, M., Qiao, M., Gunji, T., Alter, H. J. and Liang, T. J. 2003. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl Acad. Sci. USA 100:6753.
27. Grgacic, E. V. and Anderson, D. A. 2006. Virus-like particles: Passport to immune recognition. Methods 40:60.
28. Kuhn, R. Y., Zhang, W., Rossman, M. G. et al. 2002. Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell 108:717.
29. Yauch, L. E. and Shresta, S. 2008. Mouse models of dengue virus infection and disease. Antiviral Res. 80:87.
30. Rothman, A. L., Kurane, I., Lai, J. C. et al. 1993. Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes. J. Virol. 67:801.
31. Rothman, A. L., Kurane, I. and Ennis, F. A. 1996. Multiple specificities in the murine CD4+ and CD8 + T-cell response to dengue virus. J. Virol. 70:6540.
32. Mukhopadhyay, S., Kuhn, R. J. and Rossmann, M. G. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3:13.
33. Brinton, M. A. and Perelygin, A. A. 2003. Genetic resistance to flaviviruses. Adv. Virus Res. 60:43.
34. Shresta, S., Kyle, J. L., Snider, H. M., Basavapatna, M., Beatty, P. R. and Harris, E. 2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J. Virol. 78:2701.
35. Ackerman, A. L., Giodini, A. and Cresswell, P. 2006. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 25:607.
36. Chung, Y. C., Ho, M. S., Wu, J. C. et al. 2008. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26:1855.
37. Gagnon, S. J., Ennis, F. A. and Rothman, A. L. 1999. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+ cytotoxic T-lymphocytes clones. J. Virol. 73:3623.
38. Vollmer, J. 2006. CpG motifs to modulate innate and adaptative immune response. Int. Rev. Immunol. 25:125.
39. Riedl, P., Stober, D., Oehninger, C., Melber, K., Reimann, J. and Schirmbeck, R. 2002. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J. Immunol. 168:4951.
40. Donnelly, J., Berry, K. and Ulmer, J. B. 2003. Technical and regulatory hurdles for DNA vaccines. Int. J. Parasitol. 33:457.
41. Takeshita, F., Leifer, C. A., Gursel, I. et al. 2001. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167:3555.
42. Van der Most, R. G., Murali-Krishna, K. and Ahmed, R. 2003. Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis. Intern. Immunol. 15:119.
43. Aihara, H., Takasaki, T., Matsutani, T., Suzuki, R. and Kurane, I. 1998. Establishment and characterization of Japanese encephalitis virus-specific human CD4 T-cell clones: Flavivirus cross-reactivity, protein recognition, and cytotoxic activity. J. Virol. 72:8032.
44. Green, S., Kurane, I., Eldelman, R. et al. 1993. Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: Bulk culture proliferation, clonal analysis and precursor frequency determination. J. Virol. 67:5962.
45. Berrios, V., Kurane, I. and Ennis, F. A. 1996. Immunomodulatory effects of IL-7 on dengue virus-specific cytotoxic CD4+ T cell clones. Immunol. Invest. 25:231.
46. Dharakul, T., Bhamarapravati, N., Yoksan, S., Vaughn, D. W., Hoke, C. H. and Ennis, F. A. 1994. Dengue virus-specific memory T cell responses in human volunteers receiving a live-attenuated dengue virus type 2 candidate vaccine. J. Infect. Dis. 170:27.
47. Rothman, A. L., Kanesa-thasan, N., West, K., Saluzzo, J. F. and Ennis, F. A. 2001. Induction of lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue vaccine. Vaccine 19:4695.
48. Sabchareon, A., Lang, J., Chanthavanich, P. et al. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccine in Tahi adult volunteers: Role of serotype concentration, ratio and multiple doses. Am. J. Trop. Med. Hyg. 66:264.
49. Wu, S. F., Liao, C. L., Lin, Y. L. et al. 2003. Evaluation of protective efficacy and immune mechanism of using a non-structural protein NS1 in DNA vaccine against dengue 2 in mice. Vaccine 21:3919.
50. Zivny, J., DeFronzo, M., Jarry, W. et al. 1999. Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. J. Immunol. 163:2754.